Clinical Trial: Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors
Study Status: Completed
Recruit Status: RECRUITING
Condition: Breast Cancer
Study Type: INTERVENTIONAL
Official Title: Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Antitumor Activity of TNG348 Single Agent and in Combination With a PARP Inhibitor in Patients With
Brief Summary:
The goal of this interventional clinical trial is to learn about TNG348, a ubiquitin specific peptidase 1 (USP1) inhibitor, alone and in combination with olaparib in patients with BRCA 1/2 mutant or HRD+ solid tumors.The main question[s] it aims to answer are:to evaluate the safety and tolerability of single agent and combination therapyto determine the recommended dose for Phase 2 of single agent and combination therapyto determine the pharmacokinetics of TNG348 as a single agent and in combination therapyto…
Read more